02 08 09 03 product pipeline Technology Client licensee Drug Therapeutic category Feasibility Oral GlaxoSmithKline Paxil CR CNS Sanofi-Synthlabo Xatral OD UroXatral Genito-Urinary Roche Madopar DR Parkinsons Disease Therabel Coruno Angina Mundipharma Nifedipine Hypertension Ratiopharm Diclofenac Arthritis GlaxoSmithKline Requip Parkinsons Disease Critical Therapeutics Zileuton Asthma COPD Merck KGaA Undisclosed Undisclosed Kowa Statin NK-104 Cardiovascular Undisclosed Undisclosed Undisclosed King Altace Hypertension Inhalation Novartis Foradil Certihaler Asthma AstraZeneca Pulmicort HFA Asthma SkyePharma Formoterol HFA Asthma Novartis QAB 149 Asthma COPD SkyePharma Formoterol Combi Asthma Injectable Enzon Mundipharma Nippon DepoCyt Oncology Endo Medeus DepoMorphine Acute Pain Astralis Psoraxine Psoriasis SkyePharma DepoBupivacaine Local Anaesthetic SkyePharma HGH Growth Disorders GeneMedix Interferon alpha-2b Anti-viral Oncology Chugai Undisclosed Undisclosed Topical Quintiles Shire Solaraze Actinic Keratosis Trigenesis Multiple Dermal Solubilisation SkyePharma Fenofibrate Cardiovascular Endo SkyePharma Propofol IDD-D Anaesthesia Sedation SuperGen Busulfan Oncology Baxter Multiple Undisclosed In addition there are a number of early stage and internal development projects at various stages for each of the technology platforms.
Feasibility Oral 5 Inhalation 2 In vitro laboratory feasibility Injectable 5 Solubilisation 4 study to determine whether, under laboratory conditions, Through a service agreement, SkyePharma is providing development, manufacturing, pre-clinical and clinical development services the formulation of the product to Astralis for second generation Psoraxine, up to completion of Phase II studies.
In the event that Phase II studies are successfully candidate can be achieved.
completed, Astralis will offer SkyePharma the option to acquire worldwide licensing and distribution rights to Psoraxine.
SkyePharma has licensed its dermatology assets to Trigenesis.
The status of the most advanced product is shown in the above chart.
SkyePharma annual report 2003 Phase I Phase II Phase III Filed Approved Marketed Phase I Filed Phase II Phase III Approved Marketed First stage of human Additional in vivo testing Trials in an expanded SkyePharma or its partners Approved by the relevant Marketed by partner clinical testing for may be performed also patient population, file for regulatory approval regulatory authority, or licensee.
toxicity in healthy called pre-pivotal trials typically at dispersed sites.
in the jurisdictions in which awaiting launch.
involving a small patient All of the improved outcome it is intended that the population to evaluate or new products under product will be marketed.
development require For example, in the US, a Phase III trial.
this will require filing Also called pivotal trials.
with the FDA and in the European community with the EMEA.
